论文部分内容阅读
据美国德托纳消息,从健康的亲属取出LAK(淋巴细胞活素激活的杀伤细胞,Lym-phokine activated killer)后再注入癌瘤病人,可能与处于危险的移植病人的移植物/宿主反应属同一性质的抗癌方法。发明本治疗的医师、威斯康星大学肿瘤学副教授Paul Sondel说,Ⅰ期临床试验的12名晚期转移癌病人中有1例完全缓解。他制备的LAK细胞不同于Rosenberg制备的LAK细胞。他制备的LAK细胞能识别组织相容性分子——存在于所有组织的移植抗原。被激活的
According to Dyton, USA, LAK (lymph-activated killer cells, Lym-phokine activated killer) is removed from healthy relatives and injected into patients with cancerous tumors. It may be related to graft/host response in at-risk transplant patients. The same nature of the anti-cancer method. The physician who invented the treatment, Paul Sondel, associate professor of oncology at the University of Wisconsin, said that 1 out of 12 patients with advanced metastatic cancer in the Phase I clinical trial had complete remission. He prepared LAK cells different from LAK cells prepared by Rosenberg. The LAK cells he prepared recognize histocompatibility molecules - transplant antigens that are present in all tissues. Activated